Status:
COMPLETED
Surgical Ablation for Atrial Fibrillation
Lead Sponsor:
Nanjing Medical University
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-85 years
Brief Summary
Minimally invasive approaches for surgical treatment have been advocated as a treatment option for stand-alone atrial fibrillation (AF). This study will investigate the clinical outcomes after minimal...
Detailed Description
Atrial fibrillation (AF) patients with a previous stroke are often at a high risk of recurrent stroke and bleeding. Minimally invasive approaches for surgical treatment have been advocated as a treatm...
Eligibility Criteria
Inclusion
- Patients age \> 18 years
- Patients with paroxysmal, or persistent/long-standing persistent AF according to the standard EHRA definition.
- Patients with symptomatic AF that is refractory to at least one antiarrhythmic medication.
- Absence of significant structural heart disease (dilated cardiomyopathy, hypertrophic cardiomyopathy, valvular heart disease, untreated coronary artery disease)
Exclusion
- AF secondary to a reversible cause (i.e., thyreopathy, etc.) Indication for open-heart surgery (coronary artery bypass grafting, valve surgery, etc.)
- Severe left ventricle dysfunction that is clearly caused by some other cardiac disease (dilated cardiomyopathy, ischaemic heart disease, etc.) where the AF is clearly of secondary etiology
- Known severe pericardial and pleural adhesions (e.g., history of cardiac surgery)
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2020
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04398979
Start Date
January 1 2012
End Date
February 1 2020
Last Update
May 22 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.